Stock Evaluator: NextCure, Inc. (NXTC)

NextCure, Inc. NXTC

$4.15 -0.89 -17.59%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 384,040
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics NXTC Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $15.0 $252.6 8%
Shares Out (Mil) 5.2 52.3 14%
Institutional Ownership 96.4% 92.1% 70%
Float (Mil) 1.9 40.2 5%
Beta 1.42 0.95 80%
Avg Daily Volume (000s) 552 455 61%
Price Change
(52-week)
(17.3%) 52.9% 32%
Growth NXTC Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (8.8%) (9.9%) 30%
EPS (5yr) (4.2%) 16.0% 26
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 13.2% (15.6%) 71%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 4
Current EPS ($1.923) ($7.463) ($7.065)
Month Ago EPS ($1.920) ($7.323) ($8.310)
# Rev Up 1 1 1
# Rev Down 0 0 0
Three Months Ago EPS ($2.000) ($8.207) ($6.310)
Year/Year Chg 2.8% (62.0%) (77.9%)
Financials NXTC Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $38 na
Net Income (TTM) (Mil) ($55) ($43) 15%
EPS (TTM) ($15.317) ($1.600) 3%
Operating Cash Flow (TTM) (Mil) ($50) ($31) 9%
Net Cash Flow (TTM) (Mil) ($7) $5 33%
Long-Term Debt (Q1) (Mil) $4 $5 23%
Enterprise Value (Q1) (Mil) ($1) $180 3%
Valuation NXTC Industry
Median
Percentile
(All Stocks)
P/B 0.56 2.56 10%
P/E na 19.0 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios NXTC Industry
Median
Percentile
(All Stocks)
Gross Margin na 63.8% na
Net Margin na (67.3%) na
ROA (104.0%) (49.8%) 5%
ROE (132.4%) (55.5%) 7%
Liabilities to Assets 29.7% 30.3% 21%
F-Score 1 3 1%

NextCure, Inc. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors